New kind of trial aims to speed cancer drug development

Reuters: Thu Apr 17, 2014

(Reuters) – Scientists and drugmakers are pioneering a new kind of clinical trial that changes the way cancer drugs are studied, potentially cutting both the time and cost of bringing them to market.

Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial.

The aim is to quickly pinpoint medicines that can fight advanced lung cancer by targeting specific rare genetic mutations – and it upends the normal approach of putting a particular drug at the centre of a study.